J. Chapman

发表

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

V. Bramwell, A. Chambers, Lei Han, 2014, Breast Cancer Research.

Competing risks analyses for recurrence from primary breast cancer

J. Chapman, E. Fish, M. Link, 1999, British Journal of Cancer.

Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.

J. Ingle, P. Goss, W. Parulekar, 2008, Journal of the National Cancer Institute.

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial

Bingshu E. Chen, T. Nielsen, K. Gelmon, 2015, British Journal of Cancer.

NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.

T. Whelan, M. Levine, W. Parulekar, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

H. Linden, J. Ingle, J. St. Louis, 2014, The Lancet. Oncology.

NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.

T. Whelan, W. Parulekar, L. Pierce, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

M. Ellis, G. Sledge, J. Ingle, 2017, Cancer.

Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial.

P. Richardson, K. Pritchard, M. Pollak, 2006, Journal of Clinical Oncology.

Statistical Ramifications of Linear Analogue Scales in Assessing the Quality of Life of Cancer Patients

N. Boyd, J. Etezadi-Amoli, P. Selby, 1987 .

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Krishna R. Kalari, Erin E. Carlson, Bingshu E. Chen, 2016, Cancer research.

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

M. Ellis, G. Sledge, A. L. Maître, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Competing risks of mortality by PAM50 intrinsic subtype of British Columbia tamoxifen-treated cohort of post-menopausal breast cancer patients

S. Leung, T. Nielsen, Shuzhen Liu, 2021 .

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14

M. Erlander, Yi Zhang, D. Sgroi, 2016, Breast Cancer Research and Treatment.

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29

K. Gelmon, J. Costantino, N. Wolmark, 2015, Breast Cancer Research and Treatment.

Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study.

J. Ingle, P. Goss, A. Cheung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis.

W. Hanna, M. Trudeau, J. Chapman, 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial

T. Whelan, K. Pritchard, M. Levine, 2008 .

Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial.

K. Pritchard, M. Pollak, L. Shepherd, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Sally Hunsberger, R. Gray, R. Gelber, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays

W. Hanna, K. Pritchard, D. McCready, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Donna Niedzwiecki, Edward L Korn, Michael B Atkins, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer

D. Berry, E. Feuer, W. Sauerbrei, 2018, Journal of the National Cancer Institute.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27

M. Ellis, K. Gelmon, G. Sledge, 2018, Journal of the National Cancer Institute.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.

E. Perez, K. Gelmon, H. Rugo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.

M. Ellis, G. Sledge, J. Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

T. Whelan, S. Aparicio, D. Huntsman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

T. Whelan, G. Sledge, D. Cella, 2018, Breast Cancer Research and Treatment.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

T. Whelan, K. Gelmon, J. Ingle, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

S. Aparicio, K. Gelmon, W. Parulekar, 2017, Breast Cancer Research and Treatment.

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer

D. Berry, E. Feuer, R. Gray, 2018, Journal of the National Cancer Institute.

Innovative estimation of survival using log-normal survival modelling on ACCENT database

D. Sargent, P. Catalano, R. Gray, 2013, British Journal of Cancer.

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

T. Whelan, K. Gelmon, F. O'Malley, 2013, Breast Cancer Research and Treatment.

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

T. Whelan, P. Goss, D. Walde, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

V. Bramwell, A. Chambers, Lei Han, 2014, Breast Cancer Research.

Ascertaining Prognosis for Breast Cancer in Node‐Negative Patients with Innovative Survival Analysis

K. Pritchard, D. McCready, M. Trudeau, 2006, The breast journal.

Survival From Primary Breast Cancer After Routine Clinical Use of Mammography

R. Sivaramakrishna, R. Gordon, R. Gordon, 2002, The breast journal.

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

T. Whelan, K. Gelmon, J. Ingle, 2016, Breast Cancer Research and Treatment.

Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial.

T. Whelan, J. Krook, K. Pritchard, 2010 .

Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial.

M. Ellis, G. Sledge, A. L. Maître, 2009 .

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

D. Sargent, P. Catalano, R. Gray, 2011, Journal of Clinical Oncology.

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

R. Jong, Lei Han, M. Clemons, 2015, SpringerPlus.

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

T. Whelan, S. Aparicio, K. Gelmon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer?

W. Hanna, K. Pritchard, D. McCready, 1996, European journal of cancer.

Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone.

W. Hanna, D. McCready, H. Lickley, 1996, Surgical oncology.

Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment

W. Christens-Barry, D. Axelrod, Yuejiao Fu, 2007, BMC Cancer.